



## **Certification of Substances Department**

## Certificate of suitability No. R1-CEP 2016-146 - Rev 00

- 1 Name of the substance:
- 2 DOCETAXEL
- 3 Name of holder:
- 4 SCINOPHARM TAIWAN, LTD.
- 5 No. 1, Nan-Ke 8th Road
- 6 Taiwan-74144 Shan-Hua, Tainan
- 7 Site(s) of production:
- 8 SEE ANNEX 1

	<u>Notice</u>	
NOT FOR RE	GISTRATION PURPOSES	
For filing purposes please contact ScinoPharm Taiwan to obtain a complete "controlled copy" of this CEP.		iwan x, we
		F the uding
	n- Regulatory Technical Servi S@scinopharm.com.tw)	ces ex 2)
Methanol	not more than 1000 ppm	UN 2)
Acetone	not more than 1000 ppm	
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1		
Dichloromethane	not more than 600 ppm	
Dichloromethane n-Heptane	not more than 600 ppm not more than 5000 ppm	
	ALFAULDAL MALLOSS DA	
<i>n</i> -Heptane	not more than 5000 ppm not more than 1000 ppm	(Annex 3)
n-Heptane Ethyl acetate	not more than 5000 ppm not more than 1000 ppm	(Annex 3)
<ul><li>n-Heptane</li><li>Ethyl acetate</li><li>Test for residual solvents by ion</li></ul>	not more than 5000 ppm not more than 1000 ppm chromatography not more than 5000 ppm	(Annex 3)
<ul> <li>n-Heptane</li></ul>	not more than 5000 ppm not more than 1000 ppm chromatography not more than 5000 ppm	(Annex 3) (Annex 4)
<ul> <li>n-Heptane Ethyl acetate</li> <li>Test for residual solvents by ion Acetic acid</li> <li>In the last steps of the synthesis</li> <li>A risk management summary for</li> </ul>	not more than 5000 ppm not more than 1000 ppm chromatography not more than 5000 ppm s water is used as solvent.	(Annex 4)

- The holder of the certificate has declared the absence of use of material of human or animal origin in the manufacture of the substance.
- 32 The submitted dossier must be updated after any significant change that may alter the quality,
- 33 safety or efficacy of the substance.
- 34 Manufacture of the substance shall take place in accordance with the Good Manufacturing Practice
- 35 and in accordance with the dossier submitted.
- 36 Failure to comply with these provisions will render this certificate void.
- 37 This certificate is renewed from 19 June 2022 according to the provisions of Resolution
- 38 AP-CSP (07) 1, and of Directive 2001/83/EC and Directive 2001/82/EC and any subsequent
- 39 amendment, and the related guidelines.
- 40 This certificate has four annexes, the first of 1 page, the second of 3 pages, the third of 2 pages
- 41 and the fourth of 1 page.
- 42 This certificate has:
- 43 lines.

On behalf of the

## NOT FOR REGISTRATION PURPOSES

For filing purposes please contact ScinoPharm Taiwan to obtain a complete "controlled copy" of this CEP.

ScinoPharm Taiwan- Regulatory Technical Services (SPT.RTS@scinopharm.com.tw)

hereby authorises .	
	(name of the pharmaceutical company)

to use the above-mentioned certificate of suitability in support of their application(s) for the following Marketing Authorisation(s): (name of product(s) and marketing number(s), if known)

The holder also certifies that no significant changes to the operations as described in the CEP dossier have been made since the granting of this version of the certificate.

Date and Signature (of the CEP holder):